Advertisement
U.S. markets open in 5 hours 14 minutes
  • S&P Futures

    5,303.75
    -4.50 (-0.08%)
     
  • Dow Futures

    40,094.00
    -50.00 (-0.12%)
     
  • Nasdaq Futures

    18,491.50
    -12.25 (-0.07%)
     
  • Russell 2000 Futures

    2,133.80
    -4.60 (-0.22%)
     
  • Crude Oil

    81.86
    +0.51 (+0.63%)
     
  • Gold

    2,212.00
    -0.70 (-0.03%)
     
  • Silver

    24.55
    -0.21 (-0.84%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.94
    +0.16 (+1.25%)
     
  • dólar/libra

    1.2609
    -0.0029 (-0.23%)
     
  • USD/JPY

    151.4040
    +0.1580 (+0.10%)
     
  • Bitcoin USD

    70,410.02
    +491.00 (+0.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,950.89
    +18.91 (+0.24%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Surging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)

Exact Sciences Corporation EXAS is a molecular diagnostics company, focusing on developing products for the early detection and prevention of various cancers that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on EXAS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Exact Sciences could be a solid choice for investors.

Current Quarter Estimates for EXAS

In the past 30 days, one estimate has gone higher for Exact Sciences while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 32 cents a share 30 days ago, to a loss of 31 cents today, a move of 3.2%.

Current Year Estimates for EXAS

Meanwhile, Exact Science’s current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.22 per share 30 days ago to a loss of $1.19 per share today, an increase of 2.5%.

Exact Sciences Corporation Price and Consensus

Exact Sciences Corporation Price and Consensus | Exact Sciences Corporation Quote

Bottom Line

The stock has also started to move higher lately, adding 8.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement